anti human cd5 rea782 pe (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
93
Structured Review
Miltenyi Biotec
anti human cd5 rea782 pe
Anti Human Cd5 Rea782 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5/CD5+Antibody%2C+anti-human%2C+REAfinity/pmc08809252-102-0-5
Average 93 stars, based on 14 article reviews
Anti Human Cd5 Rea782 Pe, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5/CD5+Antibody%2C+anti-human%2C+REAfinity/pmc08809252-102-0-5
Average 93 stars, based on 14 article reviews
anti human cd5 rea782 pe - by Bioz Stars,
2026-11
93/100 stars
Images
1) Product Images from "Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches"
Article Title: Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches
Journal: Cell
doi: 10.1016/j.cell.2021.12.018
Figure Legend Snippet:
Techniques Used: Purification, Recombinant, Staining, cDNA Synthesis, Gene Expression, Software, Microscopy
Related Articles
other:Article Title: Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches Article Snippet: Staining:Article Title: A novel Vδ1 engager targeting CD19 enhances human Vδ1 γδ T cell responses against CLL and CD19+ hematological malignancies. Article Snippet: γδ T cells are associated with favorable outcomes in many cancers likely through a mechanism of stress-directed cytotoxicity and antitumor cytokine production.. Vδ1 γδ T cells are especially promising for immunotherapy due to their broad stress recognition and resistance to activation-induced cell death.. Here, we generate a CD19 engager incorporating a novel Vδ1 binding moiety as proof-of-concept for treating CD19 cancers, including Chronic Lymphocytic Leukemia (CLL). Flow Cytometry:Article Title: A novel Vδ1 engager targeting CD19 enhances human Vδ1 γδ T cell responses against CLL and CD19+ hematological malignancies. Article Snippet: γδ T cells are associated with favorable outcomes in many cancers likely through a mechanism of stress-directed cytotoxicity and antitumor cytokine production.. Vδ1 γδ T cells are especially promising for immunotherapy due to their broad stress recognition and resistance to activation-induced cell death.. Here, we generate a CD19 engager incorporating a novel Vδ1 binding moiety as proof-of-concept for treating CD19 cancers, including Chronic Lymphocytic Leukemia (CLL). Article Title: Method for transduction of t cells in the presence of malignant cells Article Snippet: .. Malignant B cells were characterized by evaluation of surface markers using flow cytometry: CD45-Vioblue (Miltenyi Biotec, cat. No. 130-110-637), IgKappa-Viogreen (Miltenyi Biotec, cat. No. 130-122-224), IgLambda-APC-Vio (Miltenyi Biotec, cat. No. 130-105-106), |
